An exploratory study of the patient experience of pharmacist supplementary prescribing in a secondary care mental health setting

Main Article Content

Rhian Deslandes
Dai N. John
Paul N. Deslandes


Pharmacists, Drug Prescriptions, Mental Disorders, Attitude to Health, Professional Role, Great Britain


Background: Management of chronic disease has become an increasing challenge to the National Health Service in the United Kingdom. The introduction of supplementary prescribing was seen as a possible mechanism to address the needs of this patient group. Individuals with mental illness were considered particularly suitable for management in this way.

Objective: To explore the views and experiences of patients with mental illness on being managed by a pharmacist supplementary prescriber in a secondary care outpatient setting.

Methods: A study of patient experiences utilising semi-structured interviews and self-completion diaries was adopted. Eleven patients participated in the study. Data were analysed utilising code and retrieve, and content analysis respectively.

Results: Patients valued the increased accessibility to, and continuity of, their prescriber compared with their experience of other healthcare professionals. Patients reported they were able to trust the pharmacist’s knowledge of medication, were provided with sufficient information regarding reasons for treatment and side effects, and felt that they had an active role in decisions concerning their healthcare.

Conclusions: This exploratory study showed that patients had positive views of being managed by a supplementary prescriber. However, it should be noted that the number of participants was small. It is therefore important that further, more wide ranging research is conducted to evaluate pharmacist prescribing within mental health settings.

Abstract 3129 | PDF Downloads 1315


1. Department of Health. Improving Chronic Disease Management. London: Department of Health; 2004.

2. Department of Health. Review of Prescribing, Supply and Administration of Medicines. Final Report. London: Department of Health; 1999.

3. Emmerton L, Marriott J, Bessell T, Nissen L, Dean L. Pharmacists and prescribing rights: review of international developments. J Pharm Pharm Sci. 2005;8(2):217-225.

4. Department of Health. New ways of working for psychiatrists: Enhancing effective, person-centred services through new ways of working in multidisciplinary and multi-agency context. Final report. ‘But not the end of the story’. London: Department of Health; 2005.

5. Medicines Control Agency and Department of Health. Proposals for supplementary prescribing by nurses and pharmacists and proposed amendments to the prescription only medicines (human use) order 1997. Consultation document MLX 284. London: Medicines Control Agency and Department of Health; 2002.

6. UK Psychiatric Pharmacy Group and College of Mental Health Pharmacists. Joint Position Statement on Specialist Pharmacist Supplementary Prescribing in Mental Health and Learning Disabilities. 2003. Available from: (accessed 1 August 2007).

7. Tonna A, Stewart D, West B, McCaig D. Pharmacist prescribing in the UK – a literature review of current practice and research. J Clin Pharm Ther. 2007;32(6):545-556.

8. Cooper R, Anderson C, Avert T, Bissell P, Guillaume L, Hutchinson A, James V, Lymn L, McIntosh A, Murphy E, Ratcliffe J, Read, S, Ward, P. Nurse and pharmacist supplementary prescribing in the UK – A thematic review of the literature. Health Policy. 2008;85(3):277-292.

9. Department of Health. Creating a patient-led NHS. Delivering the NHS improvement plan. London: Department of Health; 2005.

10. Lloyd F, Hughes R, Little K, Lynch C, Hughes, C. Patient views on pharmacist supplementary prescribing. Int J Pharm Pract. 2007;15(Suppl 2):B63.

11. Stewart D, George J, Bond C, Cunningham S, Diack L, McCaig D. Exploring patient perspectives of pharmacist supplementary prescribing in Scotland. Pharm World Sci. 2008;30(6):892-897. doi: 10.1007/s11096-008-9248-x

12. Stewart D, George J, Bond C, Diack L, McCaig D, Cunningham S. Views of pharmacist prescribers, doctors and patients on pharmacist prescribing implementation. Int J Pharm Pract. 2009;17(2):89-94.

13. Hobson R, Scott J, Sutton J. Pharmacists and nurses as independent prescribers: exploring the patient’s perspective. Fam Pract. 2010;27(1):110-120. doi: 10.1093/fampra/cmp070

14. Gray R, Rofail D, Allen J, Newey T. A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication. J Adv Nurs. 2005;52(1):31-37.

15. Gillham B. Case Study Research Methods. London: Continuum; 2000.

16. Richardson A. The health diary: An examination of its use as a data collection method. J Adv Nurs. 1994;19(4):782-791.

17. Verbrugge LM. Health diaries. Med Care. 1980;18(1):73-95.

18. Zimmerman D, Wieder D. The diary. Diary-interview method. Urban Life. 1977;5(4):479-498.

19. Babbie E. The Practice of Social Research, 11th edn. Australia: Thomson Wadsworth; 2007.

20. Neuendorf KA. The Content Analysis Guidebook. London: Sage; 2002.

21. Weiss M, Sutton J, Adams C. Exploring innovation in pharmacy practice: A qualitative evaluation of supplementary prescribing by pharmacists. London: Royal Pharmaceutical Society of Great Britain; 2006.

22. Stewart D, MacLure K, Bond C, Cunningham S, Diack L, George J, McCaig D. Pharmacist prescribing in primary care: the views of nominated patients across Great Britain who had experienced the service. Int J Pharm Pract. 2010;18(Suppl 2):15-16.

23. George J, McCaig D, Bond C, Cunningham S, Diack L, Watson A, Stewart D. Supplementary prescribing: Early experiences of pharmacist in Great Britain. Ann Pharmacother. 2006;40(10):1843-1850.

24. Cooper R, Anderson C, Avery T, Bissell P, Guillame L, Hutchinson A, Lymn J, Murphy E, Ratcliffe J, Ward P. Stakeholders’ views of UK nurse and pharmacist supplementary prescribing. J Health Serv Res Policy. 2008;13(4):215-221. doi: 10.1258/jhsrp.2008.008004

25. McCann L, Hughes C, Lloyd F, Haughey S, Parsons C, Creale, G, Gormley G. Pharmacy prescribing in XXXX – a quantitative assessment. Int J Pharm Pract. 2010;18(Suppl 2):90-91.

26. McCann L, Hughes C, Lloyd F, Haughey S, Parsons, C, Crealey, G, Gormley G. Pharmacy prescribing in XXXX – a qualitative assessment. Int J Pharm Pract. 2010;18(Suppl 2):91-92.

27. National Institute for Health and Clinical Excellence Bipolar Disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Clinical Guideline 38. London: NICE; 2006.

28. Knox K, Fejzic J, Mey A, Fowler JL, Kelly F, McConnell D, Hattingh L, Wheeler AJ. Mental health consumer and caregiver perceptions of stigma in Australian community pharmacies. Int J Soc Psychiatry. 2014;60(6):533-543. doi: 10.1177/0020764013503149

29. Hattingh HL, Knox K, Fejzic J, McConnell D, Fowler JL, Mey A, Kelly F, Wheeler AJ. Privacy and confidentiality: perspectives of mental health consumers and carers in pharmacy settings. Int J Pharm Pract. 2015;23(1):52-60. doi: 10.1111/ijpp.12114

30. Knox K, Kelly F, Mey A, Hattingh L, Fowler JL, Wheeler AJ. Australian mental health consumers’ and carers’ experiences of community pharmacy service. Health Expect. 2014 [Epub ahead of print]. doi: 10.1111/hex.12179

31. Care Quality Commission. Community mental health services survey 2010. 2010. Available from: (accessed 24 September 2010).

32. Morgan S, Yoder L. A concept analysis of person-centred care. J Holist Nurs. 2012;30(1):6-15. doi: 10.1177/0898010111412189

33. Tawab R, Davies J, Horne R, James D. Evaluating pharmaceutical consultations: a validation of the medication-related consultation framework (MRCF). Int J Pharm Pract. 2005;13(Suppl):R27.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>